Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
MENS
STRONG SELLREMOVEJyong Biotech Ltd. · Healthcare · Taiwan · $121M · Avg Vol: $142K/d
Jyong Biotech is a small-scale healthcare player lacking the scale, regulatory moats, or global CDMO capabilities needed to capture the pharmaceutical pricing power cycle.
COMPANY DESCRIPTION
Jyong Biotech Ltd. is a Taiwanese biotechnology company likely engaged in the research and development of novel therapeutic candidates or advanced diagnostic solutions. Operating in the highly competitive healthcare sector, the company aims to establish a competitive moat through proprietary technology and an innovative product pipeline addressing specific unmet medical needs. Its success is contingent on scientific breakthroughs and successful commercialization within the R&D-intensive biotech industry.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | — | 0 | 0 | 0 | 0 | — |
| EPS | -0.06 | -0.09 | -0.06 | -0.04 | — | — |
| Shares | — | 76.0M | 76.0M | 76.0M | 76.0M | 0.0% |
| Debt | — | 14.3M | 16.7M | 18.1M | 18.5M | 9.2% |
| Equity | — | -29.6M | -34.1M | -36.5M | -24.9M | — |
| Op CF | — | -3.0M | -2.6M | -3.6M | -3.0M | — |
| Inv CF | — | 1.4M | 95,000 | 0 | -13.5M | — |
| Fin CF | — | 3.3M | 2.0M | 2.0M | 17.6M | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of MENS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| MENS | Jyong Biotech Ltd.(you) | $121M | 4 | STRONG SELL |
| 4174.TWO | OBI Pharma, Inc. | $116M | 1 | STRONG SELL |
| 4726.TWO | Mycenax Biotech Inc. | $160M | 5 | STRONG SELL |
| 6657.TW | Energenesis Biomedical CO.,LTD. | $101M | 8 | STRONG SELL |
| 4178.TW | StemCyte International, Ltd. | $117M | 12 | STRONG SELL |
| 6461.TWO | Intech Biopharm Corporation | $84M | 6 | STRONG SELL |
| 6885.TW | BRIM Biotechnology, Inc. | $91M | 9 | STRONG SELL |
| 6838.TW | Formosa Pharmaceuticals, Inc. | $116M | 15 | STRONG SELL |
| 6733.TWO | BioGend Therapeutics Co., Ltd. | $102M | 12 | STRONG SELL |
| 6492.TWO | Senhwa Biosciences, Inc. | $121M | 17 | STRONG SELL |
Peer medians: ROE 3.5% · P/E 16.2x · Gross margin 42.1%